Our data reveal an essential role of circFNDC3B in CRC, and indicate that targeting circFNDC3B/FXR2/RNF41/ASB6 signaling may be a promising avenue for CRC therapy. The gene discussed is FXR2; the disease is colorectal carcinoma.